Critically Ill COVID-19 Patients Exhibit Anti-SARS-CoV-2 Serological Responses
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is a global health care emergency. Anti-SARS-CoV-2 serological profiling of critically ill COVID-19 patients was performed to determine their humoral response. Blood was collected from critically ill ICU patients, either COVID-19 positive (+...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Pathophysiology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1873-149X/28/2/14 |
| _version_ | 1797520682217635840 |
|---|---|
| author | Douglas D. Fraser Gediminas Cepinskas Marat Slessarev Claudio M. Martin Mark Daley Maitray A. Patel Michael R. Miller Eric K. Patterson David B. O’Gorman Sean E. Gill Ian Higgins Julius P. P. John Christopher Melo Lylia Nini Xiaoqin Wang Johannes Zeidler Jorge A. Cruz-Aguado |
| author_facet | Douglas D. Fraser Gediminas Cepinskas Marat Slessarev Claudio M. Martin Mark Daley Maitray A. Patel Michael R. Miller Eric K. Patterson David B. O’Gorman Sean E. Gill Ian Higgins Julius P. P. John Christopher Melo Lylia Nini Xiaoqin Wang Johannes Zeidler Jorge A. Cruz-Aguado |
| author_sort | Douglas D. Fraser |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is a global health care emergency. Anti-SARS-CoV-2 serological profiling of critically ill COVID-19 patients was performed to determine their humoral response. Blood was collected from critically ill ICU patients, either COVID-19 positive (+) or COVID-19 negative (−), to measure anti-SARS-CoV-2 immunoglobulins: IgM; IgA; IgG; and Total Ig (combined IgM/IgA/IgG). Cohorts were similar, with the exception that COVID-19+ patients had a greater body mass indexes, developed bilateral pneumonias more frequently and suffered increased hypoxia when compared to COVID-19- patients (<i>p</i> < 0.05). The mortality rate for COVID-19+ patients was 50%. COVID-19 status could be determined by anti-SARS-CoV-2 serological responses with excellent classification accuracies on ICU day 1 (89%); ICU day 3 (96%); and ICU days 7 and 10 (100%). The importance of each Ig isotype for determining COVID-19 status on combined ICU days 1 and 3 was: Total Ig, 43%; IgM, 27%; IgA, 24% and IgG, 6%. Peak serological responses for each Ig isotype occurred on different ICU days (IgM day 13 > IgA day 17 > IgG persistently increased), with the Total Ig peaking at approximately ICU day 18. Those COVID-19+ patients who died had earlier or similar peaks in IgA and Total Ig in their ICU stay when compared to patients who survived (<i>p</i> < 0.005). Critically ill COVID-19 patients exhibit anti-SARS-CoV-2 serological responses, including those COVID-19 patients who ultimately died, suggesting that blunted serological responses did not contribute to mortality. Serological profiling of critically ill COVID-19 patients may aid disease surveillance, patient cohorting and help guide antibody therapies such as convalescent plasma. |
| first_indexed | 2024-03-10T08:00:05Z |
| format | Article |
| id | doaj.art-6960a28a78834eaca9b17785d0309532 |
| institution | Directory Open Access Journal |
| issn | 1873-149X |
| language | English |
| last_indexed | 2024-03-10T08:00:05Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathophysiology |
| spelling | doaj.art-6960a28a78834eaca9b17785d03095322023-11-22T11:31:57ZengMDPI AGPathophysiology1873-149X2021-05-0128221222310.3390/pathophysiology28020014Critically Ill COVID-19 Patients Exhibit Anti-SARS-CoV-2 Serological ResponsesDouglas D. Fraser0Gediminas Cepinskas1Marat Slessarev2Claudio M. Martin3Mark Daley4Maitray A. Patel5Michael R. Miller6Eric K. Patterson7David B. O’Gorman8Sean E. Gill9Ian Higgins10Julius P. P. John11Christopher Melo12Lylia Nini13Xiaoqin Wang14Johannes Zeidler15Jorge A. Cruz-Aguado16Lawson Health Research Institute, London, ON N6C 2R5, CanadaLawson Health Research Institute, London, ON N6C 2R5, CanadaLawson Health Research Institute, London, ON N6C 2R5, CanadaLawson Health Research Institute, London, ON N6C 2R5, CanadaLawson Health Research Institute, London, ON N6C 2R5, CanadaDepartment of Computer Science, Western University, London, ON N6A 3K7, CanadaLawson Health Research Institute, London, ON N6C 2R5, CanadaLawson Health Research Institute, London, ON N6C 2R5, CanadaLawson Health Research Institute, London, ON N6C 2R5, CanadaLawson Health Research Institute, London, ON N6C 2R5, CanadaDiagnostics Biochem Canada, London, ON N6M 1A1, CanadaDiagnostics Biochem Canada, London, ON N6M 1A1, CanadaDiagnostics Biochem Canada, London, ON N6M 1A1, CanadaDiagnostics Biochem Canada, London, ON N6M 1A1, CanadaDiagnostics Biochem Canada, London, ON N6M 1A1, CanadaDiagnostics Biochem Canada, London, ON N6M 1A1, CanadaDiagnostics Biochem Canada, London, ON N6M 1A1, CanadaCoronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is a global health care emergency. Anti-SARS-CoV-2 serological profiling of critically ill COVID-19 patients was performed to determine their humoral response. Blood was collected from critically ill ICU patients, either COVID-19 positive (+) or COVID-19 negative (−), to measure anti-SARS-CoV-2 immunoglobulins: IgM; IgA; IgG; and Total Ig (combined IgM/IgA/IgG). Cohorts were similar, with the exception that COVID-19+ patients had a greater body mass indexes, developed bilateral pneumonias more frequently and suffered increased hypoxia when compared to COVID-19- patients (<i>p</i> < 0.05). The mortality rate for COVID-19+ patients was 50%. COVID-19 status could be determined by anti-SARS-CoV-2 serological responses with excellent classification accuracies on ICU day 1 (89%); ICU day 3 (96%); and ICU days 7 and 10 (100%). The importance of each Ig isotype for determining COVID-19 status on combined ICU days 1 and 3 was: Total Ig, 43%; IgM, 27%; IgA, 24% and IgG, 6%. Peak serological responses for each Ig isotype occurred on different ICU days (IgM day 13 > IgA day 17 > IgG persistently increased), with the Total Ig peaking at approximately ICU day 18. Those COVID-19+ patients who died had earlier or similar peaks in IgA and Total Ig in their ICU stay when compared to patients who survived (<i>p</i> < 0.005). Critically ill COVID-19 patients exhibit anti-SARS-CoV-2 serological responses, including those COVID-19 patients who ultimately died, suggesting that blunted serological responses did not contribute to mortality. Serological profiling of critically ill COVID-19 patients may aid disease surveillance, patient cohorting and help guide antibody therapies such as convalescent plasma.https://www.mdpi.com/1873-149X/28/2/14COVID-19intensive care unithumoral responseserologyimmunoglobulinsoutcome |
| spellingShingle | Douglas D. Fraser Gediminas Cepinskas Marat Slessarev Claudio M. Martin Mark Daley Maitray A. Patel Michael R. Miller Eric K. Patterson David B. O’Gorman Sean E. Gill Ian Higgins Julius P. P. John Christopher Melo Lylia Nini Xiaoqin Wang Johannes Zeidler Jorge A. Cruz-Aguado Critically Ill COVID-19 Patients Exhibit Anti-SARS-CoV-2 Serological Responses Pathophysiology COVID-19 intensive care unit humoral response serology immunoglobulins outcome |
| title | Critically Ill COVID-19 Patients Exhibit Anti-SARS-CoV-2 Serological Responses |
| title_full | Critically Ill COVID-19 Patients Exhibit Anti-SARS-CoV-2 Serological Responses |
| title_fullStr | Critically Ill COVID-19 Patients Exhibit Anti-SARS-CoV-2 Serological Responses |
| title_full_unstemmed | Critically Ill COVID-19 Patients Exhibit Anti-SARS-CoV-2 Serological Responses |
| title_short | Critically Ill COVID-19 Patients Exhibit Anti-SARS-CoV-2 Serological Responses |
| title_sort | critically ill covid 19 patients exhibit anti sars cov 2 serological responses |
| topic | COVID-19 intensive care unit humoral response serology immunoglobulins outcome |
| url | https://www.mdpi.com/1873-149X/28/2/14 |
| work_keys_str_mv | AT douglasdfraser criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT gediminascepinskas criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT maratslessarev criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT claudiommartin criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT markdaley criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT maitrayapatel criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT michaelrmiller criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT erickpatterson criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT davidbogorman criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT seanegill criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT ianhiggins criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT juliusppjohn criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT christophermelo criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT lylianini criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT xiaoqinwang criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT johanneszeidler criticallyillcovid19patientsexhibitantisarscov2serologicalresponses AT jorgeacruzaguado criticallyillcovid19patientsexhibitantisarscov2serologicalresponses |